ADBRY

Peak

tralokinumab-ldrm

Leo Pharma
BLAINJECTIONINJECTABLE
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100

Mechanism of Action

Interleukin-13 Antagonists

Pharmacologic Class:

Interleukin-13 Antagonist

Indications (4)

moderate-to-severe atopic dermatitis in adultsolder whose disease is not adequately controlled with topical prescription therapiesthose therapies are not advisableatopic dermatitis
Company
Leo Pharma
Leo Pharma
Denmark - Ballerup
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers